Lineage Cell Therapeutics, Inc. (LCTX)
Automate Your Wheel Strategy on LCTX
With Tiblio's Option Bot, you can configure your own wheel strategy including LCTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LCTX
- Rev/Share 0.0423
- Book/Share 0.3435
- PB 2.8071
- Debt/Equity 0.0289
- CurrentRatio 3.8188
- ROIC -0.2141
- MktCap 220203691.0
- FreeCF/Share -0.0996
- PFCF -9.7773
- PE -13.4508
- Debt/Assets 0.0201
- DivYield 0
- ROE -0.2242
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LCTX | Craig Hallum | -- | Buy | -- | $4 | Aug. 20, 2024 |
News
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (.
Read More
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025. “We are excite.
Read More
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at Clinical Trials.
Read More
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
Published: April 22, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This ye.
Read More
About Lineage Cell Therapeutics, Inc. (LCTX)
- IPO Date 1992-03-05
- Website https://www.lineagecell.com
- Industry Biotechnology
- CEO Brian M. Culley
- Employees 70